Researchers have initiated the first-in-human clinical trial of TherVacB, a novel therapeutic vaccine designed to cure chronic hepatitis B. This groundbreaking vaccine aims to activate CD4 T-cells, potentially offering a curative approach for the over 300 million individuals worldwide affected by hepatitis B. While other vaccines have been proposed, TherVacB distinguishes itself by its potential for antiviral efficacy.
Targeting Chronic Hepatitis B
Hepatitis B remains a significant global health challenge, with millions suffering from chronic infections. Current treatments often manage the symptoms but rarely offer a complete cure. TherVacB represents a shift towards a curative strategy by stimulating the body's own immune system to combat the virus.
Novel Mechanism of Action
The vaccine's mechanism focuses on activating CD4 T-cells, which play a crucial role in orchestrating the immune response against viral infections. By enhancing the activity of these cells, TherVacB aims to clear the hepatitis B virus from the body, leading to a potential cure.
Dynavax Initiates Phase 1/2 Trial for Herpes Zoster Vaccine Candidate
In related news, Dynavax has commenced a Phase 1/2 clinical trial for Z-1018, an investigational vaccine candidate for the prevention of herpes zoster (shingles). The trial is enrolling participants aged 50 to 69 to assess the safety, tolerability, and immunogenicity of the vaccine. A total of 440 participants will be enrolled across three study sites in Australia.
